

## Press Release

### Pharmaceuticals and medical technology will go hand in hand in future – DESITIN and cerbomed sign distribution agreement

ERLANGEN/HAMBURG, September 17th, 2015 – The medical technology company cerbomed GmbH from Erlangen and the pharmaceutical company DESITIN Arzneimittel GmbH from Hamburg have entered into a groundbreaking distribution agreement: DESITIN has been granted exclusive distribution rights in Germany by cerbomed for the transcutaneous vagus nerve stimulator *NEMOS*<sup>®</sup> for treatment of epilepsy.

The successful medium-sized independent company DESITIN has been a specialist provider and proficient partner to doctors and patients in the treatment of epilepsy for many years. By taking on the distribution of the cerbomed *NEMOS*<sup>®</sup> therapeutic device, DESITIN is now also extending its expertise in the epilepsy treatment market to the medical technology sector.

“It is important to approach epilepsy treatment in a holistic way – this ranges from suitable lifestyle choices to the use of anticonvulsants right through to neurostimulation procedures, providing a useful addition to drug therapy. Due to its non-invasiveness, transcutaneous vagus nerve stimulation is especially suitable for this approach and we can now offer it to specialists in addition to our existing medications,” said Dr. Martin Zentgraf, General Manager of DESITIN Arzneimittel GmbH.

“We are looking forward to working with DESITIN, one of the strongest partners in the epilepsy treatment sector. This partnership offers doctors competent advice and gives patients access to a comprehensive range of treatment,” said Dr. Andreas Hartlep, Chief Executive Officer of cerbomed GmbH.

Both companies will be present at the 88th Congress of the German Society for Neurology, from September 23<sup>rd</sup> until 26<sup>th</sup>, 2015, in Düsseldorf, Germany.

#### About t-VNS<sup>®</sup> with *NEMOS*<sup>®</sup>

Transcutaneous Vagus Nerve Stimulation is addressed to patients suffering from various difficult-to-treat neurological and psychiatric diseases. The t-VNS<sup>®</sup> therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.

With *NEMOS*<sup>®</sup> cerbomed developed and patented a special stimulator and a dedicated ear electrode for treatment of epilepsies with t-VNS<sup>®</sup>. The stimulator, which is connected with the ear electrode, sends out the electrical impulses. With the transcutaneous vagus nerve stimulator *NEMOS*<sup>®</sup> a targeted stimulation of the vagus nerve is possible without the need of a surgery.

## About DESITIN Arzneimittel GmbH

DESTITIN is a German independent medium-sized specialist pharmaceutical company with approximately 290 employees, predominantly located at the company site in Hamburg.

DESTITIN is also financially independent and finances its developments and investments from its own sales. As a complete pharmaceutical company, DESTITIN manufactures the majority of its products in-house.

Besides being a contractual partner of hospitals and service providers DESTITIN is committed to two innovative supply models for improving disease progression in epileptic patients.

Besides its main, domestic market in Germany, DESTITIN's anti-epileptics also help patients in Scandinavia and Eastern Europe.

For further information visit [www.desitinpharma.com](http://www.desitinpharma.com).

## About cerbomed

**Cerbomed** GmbH is an innovative medical device company located in Erlangen, Germany, that focuses on neuromodulation. The company, founded in 2005, focuses on transcutaneous Vagus Nerve Stimulation (t-VNS®), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.

The transcutaneous Vagus Nerve Stimulation received the European clearance (CE mark) for the treatment of epilepsies, depression and pain. Two clinical studies regarding the effectiveness of t-VNS® in patients with drug-resistant epilepsy and chronic migraine have been finished in 2014.

The therapy device *NEMOS*® for treatment of epilepsies is available in Germany and 11 further countries of the EU.

Please visit us on [www.cerbomed.com](http://www.cerbomed.com).

## Contact

Dr. Martin Hyca, Director Marketing & Sales  
Henkestrasse 91, DE-91052 Erlangen

+49 9131 9202 76 30

[martin.hyca@cerbomed.com](mailto:martin.hyca@cerbomed.com)

